Fig. 3 | British Journal of Cancer

Fig. 3

From: Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

Fig. 3

Reduction in skin tissue (epidermis) pHH3 is associated with ilorasertib exposure. pHH3-positive cells (%) = number of pHH3-positive cells/total number of cells enumerated. Change from baseline in pHH3 (%) = [pHH3-positive cells at post-dose (%)/pHH3-positive cells at pre-dose (%)]×100. One responder is indicated by the arrow; for the other responder, pHH3 data were not available. AUC0-8 area under the concentration-time curve from time 0 to 8 h, BID twice daily, i.v. intravenously, pHH3 phosphohistone H3, PO orally

Back to article page